VetStem Biopharma Heavily Featured in Recent Documentary About Regenerative Medicine for Domestic and Wild Animals
VetStem Biopharma was recently featured in a new film, Animal Pharm: Where Beasts Meet Biotech.
Leading Regenerative Veterinary Medicine company, VetStem Biopharma, was recently featured in a new documentary entitled Animal Pharm: Where Beasts Meet Biotech. The film focuses on regenerative veterinary medicine as a means of improving the quality of life for domestic and wild animals. Animal Pharm was recently included in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, California where it received the award for Best Nature and Animals Film.
The film heavily features VetStem and includes an interview with VetStem Founder and CEO Dr. Bob Harman. Dr. Harman explains that when he first conceived of and formed VetStem, he was called “crazy.” Over time however the thinking has evolved so that regenerative medicine is now regarded as a legitimate and valuable tool for veterinarians.
Animal Pharm also touches on the fact that advances made in regenerative veterinary medicine have begun to translate into the human medical field. Dr. Harman commented, “The film provides a great service to the public by providing legitimate education about cell therapy in the veterinary field and how this can assist the field of human stem cell therapy. Elliott and Barbara did a splendid job of producing and editing this film and I am proud that the film received such a prestigious award at the Brentwood and Pacific Palisades International Film Festival. I anticipate worldwide distribution of this great film.”
VetStem has been providing stem cell services for over 15 years for the treatment of orthopedic conditions in dogs, cats, and horses. VetStem holds exclusive licenses to a large portfolio of patents, including world-wide veterinary rights for the use of adipose-derived stem cells. In recent months, VetStem launched a human stem cell company, Personalized Stem Cells, Inc (PSC), which plans to begin human stem cell clinical trials in late 2019.